Ozurdex(®) reduces the retinal thickness in radiation maculopathy refractory to bevacizumab

Acta Ophthalmol. 2014 Dec;92(8):e694-6. doi: 10.1111/aos.12424. Epub 2014 Apr 16.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Dexamethasone / administration & dosage*
  • Drug Implants
  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Intravitreal Injections
  • Macular Edema / drug therapy
  • Macular Edema / etiology
  • Male
  • Melanoma / radiotherapy
  • Middle Aged
  • Radiation Injuries / drug therapy*
  • Radiation Injuries / etiology
  • Retina / pathology
  • Retina / radiation effects*
  • Ruthenium Radioisotopes / adverse effects*
  • Treatment Failure
  • Uveal Neoplasms / radiotherapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Drug Implants
  • Glucocorticoids
  • Ruthenium Radioisotopes
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Dexamethasone

Supplementary concepts

  • Uveal melanoma